Skip to content
Peptigraph home

IMPACT: Pemvidutide Phase 2 trial (NCT05989711)

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)

Registry record checked

At a glance

Phase
Phase 2
Status
Completed
Enrolment
212
actual
Start
27 Jul 2023 (actual)
Primary completion
25 Nov 2025 (actual)
Sponsor
Altimmune, Inc.
Design

Arms and doses

NCT05989711 study arms
ArmTypeInterventionsDescription
Pemvidutide 1.2 mgExperimentalDrug: PemvidutideNot stated
Pemvidutide 1.8 mgExperimentalDrug: PemvidutideNot stated
PlaceboPlacebo comparatorDrug: PlaceboNot stated
Endpoints

Primary endpoint

NCT05989711 primary outcomes
MeasureTime frame
Proportion of subjects achieving NASH resolution (NAFLD activity score [NAS], ballooning = 0; lobular inflammation = 0, 1) with at least a 2-point reduction in NAS without worsening of fibrosis24 weeks
Proportion of subjects achieving at least 1 stage improvement in liver fibrosis without worsening of NASH (defined as no change in the NAS, ie, the sum score for ballooning, inflammation, and steatosis)24 weeks
Incidence of Treatment Emergent Adverse Events52 weeks
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT05989711 secondary outcomes
MeasureTime frame
Proportion of subjects achieving the composite of both NASH resolution and at least 1 stage improvement of liver fibrosis at 24 weeks24 weeks
Relative change (%) in liver fat content by MRI-PDFF24 weeks and 48 weeks
Absolute change in MRI-based corrected T1 (cT1) imaging24 weeks and 48 weeks
Absolute change in alanine aminotransferase (ALT)24 weeks and 48 weeks
Absolute change in Enhanced Liver Fibrosis (ELF) score24 weeks and 48 weeks
Absolute change in Fibroscan-AST (FAST) score24 weeks and 48 weeks
Relative (%) change in body weight24 weeks and 48 weeks
Absolute changes in fasting lipids (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides)24 weeks and 48 weeks
Change in HbA1c (%)24 weeks and 48 weeks
Change in glucose (mg/dL)24 weeks and 48 weeks
Change in systolic and diastolic blood pressure (mmHg)24 weeks and 48 weeks
Change in heart rate (beats per minute)24 weeks and 48 weeks
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
75 Years
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

Sources

  1. 1A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)ClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.